<DOC>
	<DOC>NCT01261611</DOC>
	<brief_summary>The purpose of this study is to evaluate how well a new drug called Dysport RU works and how safe it is, when it is used for the treatment of cervical dystonia. Dysport RU will be compared to an approved drug called Dysport.</brief_summary>
	<brief_title>Study Comparing Short Term Efficacy of Dysport® and Dysport RU® to Placebo, and to Assess Efficacy and Safety of Dysport RU® of Subjects With Cervical Dystonia</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Dystonia with at least 18 months duration since onset. Previously untreated with Botulinum toxinA (BTXA) or B or a minimum of 14 weeks since the last injection. TWSTRS score at baseline of: Total score ≥ 30, Severity SubScale score ≥ 15, Disability SubScale score ≥ 3, Pain SubScale score ≥ 2. Known hypersensitivity to Botulinum toxin (BTX) or related compounds or any component in the study drug formulation (including cow milk protein). Pure anterocollis or pure retrocollis. In apparent remission from Cervical Dystonia. Known clinically significant underlying swallowing or respiratory abnormality which might be exacerbated by BTX treatment. Previous poor response to BTX treatment or known presence of BTX neutralising antibodies. Previous phenol or alcohol injections into the neck muscles. Previous myotomy or denervation surgery involving the neck or shoulder region.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>